Allergan plc
DelistedCIK 1578845fmd_1EEKH1HXJ1PR0X05JTWQSPR0TZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Mar 31, 2020, 34 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4,584 | 5,915 | 2,603 | 4,677 | 12,688 | 14,571 | 15,941 | 15,787 | 16,089 |
| Cost of revenue | 2,567 | 3,394 | 1,645 | 1,705 | 2,752 | 1,861 | 2,168 | 2,191 | 2,493 |
| Gross profit | 2,018 | 2,521 | 958 | 2,972 | 9,936 | 12,710 | 13,773 | 13,596 | 13,596 |
| Realized investment gains (losses) | – | (70) | 14 | – | – | – | – | – | – |
| Research and development | 307 | 403 | 191 | 606 | 2,359 | 2,576 | 2,100 | 2,266 | 1,812 |
| Selling, general and administrative | 755 | 1,172 | 831 | 2,267 | 4,482 | 4,740 | 5,017 | 4,522 | 5,944 |
| Compensation and benefits | – | 825 | 1,425 | 2,377 | 3,735 | 3,148 | 2,699 | 2,680 | – |
| Operating income | 523 | 316 | (369) | (2,567) | (3,131) | (1,826) | (5,921) | (6,248) | (4,445) |
| Interest expense | 69 | 112 | 240 | 412 | 1,193 | 1,296 | 1,096 | 911 | 783 |
| Interest and investment income | 2 | 3 | 5 | 8 | 11 | 70 | 68 | 45 | 77 |
| Other non-operating income (expense) | (67) | (71) | (254) | (431) | (1,417) | (1,007) | (4,465) | (609) | (673) |
| Income before taxes | 456 | 245 | (623) | (2,998) | (4,548) | (2,832) | (10,386) | (6,857) | (5,119) |
| Income tax expense | 197 | 147 | (155) | (514) | (1,606) | (1,897) | (6,670) | (1,771) | 146 |
| Net income from continuing operations | 259 | 98 | (468) | (2,485) | (2,942) | (935) | (3,716) | (5,086) | (5,265) |
| Net income | 261 | 97 | (750) | (1,631) | 3,915 | 14,973 | (4,126) | (5,096) | (5,271) |
| Net income to common shareholders | – | – | (750) | (1,631) | 3,683 | 14,695 | (4,404) | (5,143) | (5,271) |